Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

INDIANAPOLIS, Nov. 28 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.

The decision does not affect duloxetine's FDA-approved indications for major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and management of fibromyalgia.

Lilly submitted the chronic pain application in the second quarter of 2008 based primarily on outcomes of three clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- one positive and one that is supportive but didn't meet its primary endpoint -- in chronic low back pain. In discussions between Lilly and the FDA, agency reviewers raised questions about efficacy and dosing that revolved primarily around statistical methodology and study design.

"This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application," said John Hayes, M.D., a Lilly Research Laboratories vice president at Lilly.

Chronic pain affects more than 50 million Americans(iv) and pain is a major cause of work absenteeism, underemployment and unemployment.(v,vi,vii,viii)

About Duloxetine

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on preclinical studies, Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is bel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 Research and Markets ... "Diabetes Care Devices Market In Brazil, Russia, India ... Continuous Glucose Monitors, Testing Strips, Lancets, Insulin Pumps, Insulin ... to their offering. The BRIC diabetes care ... 1.7 Billion in 2015 and is poised to reach ...
(Date:9/3/2015)... 2015  VirtualScopics, Inc. (NASDAQ: VSCP ), ... announced today, they are collaborating with a large ... epidemiology study partnering with the Ministry of Health ... teamed up with a cardiac sonographer to acquire ... will be used to identify children with rheumatic ...
(Date:9/3/2015)... YORK , Sept. 3, 2015  The findings ... are raising disturbing questions about the company,s handling of ... LLP reports.  On September 2 nd , part ... 300 adverse events, including at least 27 fatalities, have ... disclosed a confidential study commissioned by C.R. Bard in ...
Breaking Medicine Technology:The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 2The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3
... , MADISON, N.J., Nov. 2 Quest Diagnostics Incorporated ... diagnostic testing, information and services, announced that it is ... Conference in New York City. The presentation is ... Eastern Time. , During the conference, the company will ...
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it ... Monday, November 9, 2009, following the close of the U.S. financial ... 5:00 p.m. Eastern Time on the same day to discuss these ... available for two weeks following the event. The conference call, ...
Cached Medicine Technology:Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:9/3/2015)... ... September 03, 2015 , ... William Mattar Law Offices is ... believes this does not stop at any certain demographic or segment of the population. ... one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning will allow people ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive ... Research and Policy Analysis has found physician leadership development training programs to be ... of respondents said their organizations conduct some kind of physician leadership development program, ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Florida Companies to Watch for 2015 by economic development group GrowFL ... only 50 companies in the state selected for this prestigious award, which recognizes ...
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional life ... debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , Released ... to overcoming life’s obstacles by taking full responsibility for one’s life shares 15 ...
Breaking Medicine News(10 mins):Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
... Court has issued notices to the state government and Delhi ... teacher at its Doha branch claiming Rs 1.5 million for ... after preliminary arguments on former teacher Vibha Kapur's plea, Justice ... chairman to file their replies by April 3. ...
... Hopkins Scleroderma Center together with engineers from the university's ... monitor that// checks a patient's finger for symptoms of ... device seem to be promising: ,The Ambulatory ... secured with a bandage or medical tape. It contains ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... All India Institute of Medical Sciences (AIIMS) director P. ... public relation officer filed a police complaint against him. ... relation officer of AIIMS, has filed a police complaint ... accusing Venugopal of harassment, wrongful restraint from entering office, ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
Farabeuf periosteal elevators....
OHL periosteal elevator, 19 cm, 7-1/2"....
Steinhauser periosteal elevator....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: